candesartan has been researched along with Albuminuria in 49 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 9.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 9.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "Twenty-three elderly patients with systolic hypertension completed a double-blind crossover study comparing placebo, candesartan (C) 16 mg, C32 mg, lisinopril (L) 20 mg, L40 mg and C16 mg + L20 mg." | 9.11 | Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. ( Anderson, A; Bertram, D; MacInnis, RJ; Morgan, T, 2004) |
| "Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes." | 9.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 5.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 5.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "Twenty-three elderly patients with systolic hypertension completed a double-blind crossover study comparing placebo, candesartan (C) 16 mg, C32 mg, lisinopril (L) 20 mg, L40 mg and C16 mg + L20 mg." | 5.11 | Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. ( Anderson, A; Bertram, D; MacInnis, RJ; Morgan, T, 2004) |
| "The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD." | 5.11 | Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. ( Higaki, Y; Higashihara, E; Horie, S; Hosoya, T; Kamura, K; Mochizuki, T; Nakayama, T; Nutahara, K; Shimizu, T; Tsuchiya, K; Yamamoto, N, 2005) |
| "The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction in albuminuria, in hypertensive type 2 diabetic patients with nephropathy." | 5.10 | Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. ( Carstensen, B; Christensen, PK; Hansen, BV; Parving, HH; Rossing, K, 2003) |
| "We previously reported that the angiotensin II type 1 receptor antagonist candesartan was effective in reducing blood pressure and microalbuminuria in hypertensive patients with diabetic nephropathy after angiotensin-converting enzyme (ACE) inhibitors were replaced due to side effects." | 5.10 | Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. ( Hayashi, K; Saruta, T; Sato, A; Tabata, M, 2003) |
| "Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes." | 5.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| "The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria." | 5.09 | [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]. ( Philips, JC; Scheen, AJ; Weekers, L, 2001) |
| "Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients." | 4.95 | Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. ( Feng, Y; Huang, R; Li, X; Melgiri, ND; Qin, X; Sun, Y; Wang, Y, 2017) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial." | 3.85 | Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. ( Bilous, R; Chaturvedi, N; de Zeeuw, D; Fuller, J; Klein, R; Lambers Heerspink, H; Lindhardt, M; Mischak, H; Orchard, T; Parving, HH; Persson, F; Porta, M; Rossing, P; Stalmach, A; Zürbig, P, 2017) |
| "UACR was measured at baseline and during follow-up of 2310 patients in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme." | 3.75 | Albuminuria in chronic heart failure: prevalence and prognostic importance. ( Gerstein, HC; Granger, CB; Jackson, CE; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Yusuf, S; Zetterstrand, S, 2009) |
| "We examined the effect of the dihydropyridine calcium channel blocker (CCB) benidipine, the angiotensin II type 1 receptor blocker (ARB) candesartan, and the combination of these drugs on blood pressure and kidney and vascular function in rats with salt-induced hypertension." | 3.72 | Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. ( Ina, Y; Ohno, T; Sato, H; Sonoda, R; Suzuki, K; Yao, K, 2003) |
| "In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which compared bedtime or awakening dosing of candesartan (+diuretics as needed) among subjects with home systolic BP (SBP) higher than 135 mm Hg, we evaluated 180 hypertensive patients who successfully underwent pulse wave analysis by HEM-9000AI and measured their urinary albumin/creatinine ratio (UACR) and left ventricular mass index (LVMI) (n = 144) at baseline and after 6 months of treatment." | 2.80 | Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Shimizu, M; Yano, Y, 2015) |
| "Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics." | 2.79 | Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. ( Daikuhara, H; Fukunaga, K; Ohshima, T, 2014) |
| "To study the impact of the dosing time of an angiotensin II receptor blocker (ARB) titrated by self-measured home blood pressure (HBP) on cardiorenal damage in hypertensives." | 2.75 | Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2010) |
| "Aldosterone breakthrough was seen to be equal in hypertensive patients with diabetes mellitus treated with candesartan or valsartan." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "In patients with type 2 diabetes and nephropathy, dual blockade of the renin system with an angiotensin-converting enzyme inhibitor and angiotensin receptor blocker significantly reduces albuminuria and, thus, may be renoprotective even when the doses of the agents are reduced by one half." | 2.71 | Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. ( Fujisawa, T; Ikegami, H; Kawabata, Y; Nishino, M; Noso, S; Ogihara, T; Ono, M, 2005) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "Candesartan treatment in macroalbuminuric patients significantly changed 15 of the 113 polypeptides in the diabetic renal damage pattern toward levels in normoalbuminuric patients." | 2.71 | Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. ( Christensen, PK; Hillmann, M; Kaiser, T; Mischak, H; Parving, HH; Rossing, K; Walden, M, 2005) |
| "Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
| "The regular dose of an angiotensin II type-1 receptor blocker (ARB) in renal transplant patients for hypertension is shown to be safe and effective; however, information on the appropriate dosing of ARBs in renal transplant patients is limited." | 1.37 | Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. ( Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| "Early proteinuric diabetic nephropathy increases renal expression of the p47phox component of NAD(P)H oxidase and eNOS with increased indices of systemic and renal oxidative/nitrosative stress." | 1.31 | Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. ( Fujita, T; Goto, A; Onozato, ML; Tojo, A; Wilcox, CS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (69.39) | 29.6817 |
| 2010's | 14 (28.57) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, J | 1 |
| Kim, HS | 1 |
| Min Kim, T | 1 |
| Kim, H | 1 |
| Lee, SH | 1 |
| Hyoung Cho, J | 1 |
| Lee, H | 1 |
| Woo Yim, H | 1 |
| Yoon, KH | 1 |
| Cechova, S | 1 |
| Dong, F | 1 |
| Chan, F | 1 |
| Kelley, MJ | 1 |
| Ruiz, P | 1 |
| Le, TH | 1 |
| Daikuhara, H | 2 |
| Fukunaga, K | 1 |
| Ohshima, T | 1 |
| de Seigneux, S | 1 |
| Courbebaisse, M | 1 |
| Rutkowski, JM | 1 |
| Wilhelm-Bals, A | 1 |
| Metzger, M | 1 |
| Khodo, SN | 1 |
| Hasler, U | 1 |
| Chehade, H | 1 |
| Dizin, E | 1 |
| Daryadel, A | 1 |
| Stengel, B | 1 |
| Girardin, E | 1 |
| Prié, D | 1 |
| Wagner, CA | 1 |
| Scherer, PE | 1 |
| Martin, PY | 1 |
| Houillier, P | 1 |
| Feraille, E | 1 |
| Shimizu, M | 3 |
| Hoshide, S | 3 |
| Ishikawa, J | 3 |
| Yano, Y | 3 |
| Eguchi, K | 3 |
| Kario, K | 3 |
| Lindhardt, M | 1 |
| Persson, F | 1 |
| Zürbig, P | 1 |
| Stalmach, A | 1 |
| Mischak, H | 2 |
| de Zeeuw, D | 1 |
| Lambers Heerspink, H | 1 |
| Klein, R | 2 |
| Orchard, T | 2 |
| Porta, M | 2 |
| Fuller, J | 2 |
| Bilous, R | 3 |
| Chaturvedi, N | 2 |
| Parving, HH | 4 |
| Rossing, P | 1 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Wang, Y | 1 |
| Qin, X | 1 |
| Melgiri, ND | 1 |
| Sun, Y | 1 |
| Li, X | 1 |
| Yoshida, S | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 2 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 2 |
| Kitamura, H | 2 |
| Umemura, S | 2 |
| Ikeda, H | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Shimizu, H | 1 |
| Uehara, Y | 1 |
| Ohsaki, A | 1 |
| Okada, S | 1 |
| Mori, M | 1 |
| Sjølie, AK | 1 |
| Jackson, CE | 1 |
| Solomon, SD | 1 |
| Gerstein, HC | 1 |
| Zetterstrand, S | 1 |
| Olofsson, B | 1 |
| Michelson, EL | 1 |
| Granger, CB | 1 |
| Swedberg, K | 1 |
| Pfeffer, MA | 1 |
| Yusuf, S | 1 |
| McMurray, JJ | 1 |
| Ishikawa, S | 1 |
| Shimada, K | 1 |
| Okura, T | 1 |
| Kojima, M | 1 |
| Machida, H | 1 |
| Sugiyama, M | 1 |
| Kato, T | 2 |
| Komada, T | 1 |
| Miyazaki, T | 1 |
| Ninomiya, T | 1 |
| Ichikawa, T | 1 |
| Nakatani, K | 1 |
| Watanabe, Y | 1 |
| Dohi, Y | 1 |
| Ito, M | 1 |
| Kimura, G | 1 |
| Nakagawa, N | 1 |
| Fujino, T | 1 |
| Kabara, M | 1 |
| Matsuki, M | 1 |
| Chinda, J | 1 |
| Kikuchi, K | 1 |
| Hasebe, N | 1 |
| Okumi, M | 1 |
| Kawada, N | 1 |
| Ichimaru, N | 1 |
| Abe, T | 1 |
| Imamura, R | 1 |
| Kojima, Y | 1 |
| Kokado, Y | 1 |
| Isaka, Y | 1 |
| Rakugi, H | 1 |
| Nonomura, N | 1 |
| Moriyama, T | 1 |
| Takahara, S | 1 |
| Maeda, A | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Dejima, T | 1 |
| Wakui, H | 1 |
| Yanagi, M | 1 |
| Okano, Y | 1 |
| Fujikawa, T | 1 |
| Mizushima, S | 1 |
| Tochikubo, O | 1 |
| Kikuchi, F | 1 |
| Ishida, T | 1 |
| Chen, X | 1 |
| Mori, T | 3 |
| Guo, Q | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Zhu, W | 1 |
| Jiang, Y | 1 |
| Endo, S | 1 |
| Nakayama, K | 1 |
| Ogawa, S | 3 |
| Nakayama, M | 1 |
| Miyata, T | 1 |
| Ito, S | 3 |
| Rossing, K | 2 |
| Christensen, PK | 2 |
| Hansen, BV | 1 |
| Carstensen, B | 1 |
| Yao, K | 2 |
| Sato, H | 2 |
| Sonoda, R | 1 |
| Ina, Y | 2 |
| Suzuki, K | 2 |
| Ohno, T | 2 |
| Shirakura, S | 1 |
| Sato, A | 1 |
| Tabata, M | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Makino, H | 1 |
| Morgan, T | 1 |
| Anderson, A | 1 |
| Bertram, D | 1 |
| MacInnis, RJ | 1 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| Horie, S | 1 |
| Kamura, K | 1 |
| Tsuchiya, K | 1 |
| Mochizuki, T | 1 |
| Hosoya, T | 1 |
| Nakayama, T | 1 |
| Yamamoto, N | 1 |
| Higaki, Y | 1 |
| Shimizu, T | 1 |
| Schram, MT | 1 |
| van Ittersum, FJ | 1 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 1 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 1 |
| Twisk, JW | 1 |
| Stehouwer, CD | 1 |
| Fujisawa, T | 1 |
| Ikegami, H | 1 |
| Ono, M | 1 |
| Nishino, M | 1 |
| Noso, S | 1 |
| Kawabata, Y | 1 |
| Ogihara, T | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Krimholtz, MJ | 1 |
| Karalliedde, J | 1 |
| Thomas, S | 1 |
| Viberti, G | 1 |
| Walden, M | 1 |
| Hillmann, M | 1 |
| Kaiser, T | 1 |
| Ohashi, H | 1 |
| Takagi, H | 1 |
| Ishimitsu, T | 1 |
| Kobayashi, T | 1 |
| Honda, T | 1 |
| Takahashi, M | 1 |
| Minami, J | 1 |
| Ohta, S | 1 |
| Inada, H | 1 |
| Yoshii, M | 1 |
| Ono, H | 1 |
| Matsuoka, H | 1 |
| Nako, K | 2 |
| Takeuchi, K | 2 |
| Ichihara, A | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Sakoda, M | 1 |
| Itoh, H | 1 |
| Tsubono, Y | 1 |
| Fogari, R | 1 |
| Corradi, L | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Mugellini, A | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Bramlage, P | 1 |
| Thoenes, M | 1 |
| Paar, WD | 1 |
| Bramlage, CP | 1 |
| Schmieder, RE | 1 |
| Yoneda, T | 1 |
| Takeda, Y | 1 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Takata, H | 1 |
| Yamamoto, Y | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Knudsen, ST | 1 |
| Andersen, NH | 1 |
| Poulsen, SH | 1 |
| Eiskjaer, H | 1 |
| Hansen, KW | 1 |
| Helleberg, K | 1 |
| Poulsen, PL | 1 |
| Mogensen, CE | 3 |
| Ruilope, L | 1 |
| Obata, J | 1 |
| Nakamura, T | 1 |
| Takano, H | 1 |
| Naito, A | 1 |
| Kimura, H | 1 |
| Yoshida, Y | 1 |
| Shimizu, F | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Neldam, S | 1 |
| Tikkanen, I | 1 |
| Oren, S | 1 |
| Viskoper, R | 1 |
| Watts, RW | 1 |
| Cooper, ME | 1 |
| Chen, BH | 1 |
| Philips, JC | 1 |
| Weekers, L | 1 |
| Scheen, AJ | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| Wilcox, CS | 1 |
| Hetzel, GR | 1 |
| Hermsen, D | 1 |
| Hohlfeld, T | 1 |
| Rettich, A | 1 |
| Ozcan, F | 1 |
| Fusshöller, A | 1 |
| Grabensee, B | 1 |
| Plum, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
5 reviews available for candesartan and Albuminuria
| Article | Year |
|---|---|
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2017 |
[Early diagnosis of and therapy for patients with diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
[The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2005 |
RAS blockade: new possibilities in the treatment of complications of diabetes.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2000 |
26 trials available for candesartan and Albuminuria
| Article | Year |
|---|---|
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2014 |
Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphen | 2010 |
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidaz | 2012 |
Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles | 2011 |
Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment?
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2012 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aze | 2012 |
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cros | 2003 |
Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2003 |
Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
Topics: Albuminuria; Amino Acid Sequence; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarker | 2005 |
Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimid | 2006 |
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2007 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2008 |
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2000 |
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2001 |
18 other studies available for candesartan and Albuminuria
| Article | Year |
|---|---|
The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2020 |
Topics: Actins; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 2018 |
Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling.
Topics: Adult; Albuminuria; Analysis of Variance; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Wes | 2015 |
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Com | 2017 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Topics: Age Distribution; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphen | 2009 |
Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Benzimidazo | 2011 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |
Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2003 |
Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2003 |
Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bloc | 2006 |
[Albuminuria: an indicator of cardiovascular risk].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensi | 2007 |
Diabetic nephropathy: evidence for renoprotection and practice.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2000 |
Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Benzimidazoles; Biph | 2000 |
Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Do | 2001 |
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2002 |
Effects of candesartan and perindopril on renal function, TGF-beta1 plasma levels and excretion of prostaglandins in stable renal allograft recipients.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2002 |